Mobile Site ›
Hot Topics Banner

What the FDA Relabeling of Abacavir Means for You and Your Patients



November 2008

View the presentation

An FDA safety alert reported studies linking potentially fatal hypersensitivity reactions with abacavir, an HIV-antiretroviral medication, to a specific HLA-B allele (HLA-B*5701). Testing patients for this allele, prior to receiving abacavir, is now recommended. Dr. O’Kane and Dr. Yao discuss what this means for you and your patients.

Presenters:

Print Options

Forward to a Colleague

Share this presentation.

If you have questions, e-mail


Key